Ballicules.com

Raloxifene

EVISTA

What it isSelective estrogen receptor modulator; postmenopausal osteoporosis and breast cancer risk reduction.

Why this oneIt builds bone while blocking estrogen in the breast, reducing invasive breast cancer risk — a combination estrogen cannot offer.

What limits itVenous thromboembolism and hot flushes. Vertebral fracture data only, with no hip fracture benefit.

FDA-approved for

FDA label

BOXED WARNING Increased risk of venous thromboembolism (DVT/PE) and death from stroke.
FDA dosingPopulationStartTargetMax
Osteoporosis (treatment/prevention) and reduction of invasive breast cancer riskPostmenopausal women60 mg QD60 mg QD60 mg QD

Renal Undefined

Hepatic Use with caution

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Contraindicated — may cause fetal harm; not for females of reproductive potential.

Lactation Undefined

⚠ BOXED WARNINGS

Cost, est. cash$5–$150/month

Generic entry2014

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryX

Defining liabilityVenous thromboembolism and hormone-related adverse effects; estrogen also lowers lamotrigine exposure.

Mechanism of action: Raloxifene ballicule

Raloxifene ballicule: receptor binding, kinetics and half-life diagram

Open Raloxifene in the interactive console ↗

Memory aids: mascots and interaction avatars

Raloxifene EVISTA mascot mnemonic cartoon
“Eve is a Rolex fiend”
Pink ribbon → reduces invasive breast cancer risk
Bone → SERM agonist at bone (osteoporosis)
Raloxifene Box: minimal PK interactions avatar
Box: minimal PK interactions

Open Raloxifene in the interactive console ↗